Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGOBSERVATIONAL

Biomarker-based Alzheimer's Disease Cohort Study (BASIC)

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

This study adopts a prospective cohort design, constructing a single-center cohort by recruiting patients with Alzheimer's disease (AD) who are positive for AD biomarkers. First, the investigators aim to establish a cohort of AD patients with positive biomarkers, thereby reserving suitable patient resources for future AD-related clinical trials. Second, based on the established cohort, the investigators will explore the associations between AD-related biomarkers and clinical manifestations among the elderly population in China, and identify potential risk factors influencing the progression of AD. Third, according to the identified risk factors for AD progression, the investigators will construct a risk early warning model for the progression rate of AD based on biomarkers, in order to achieve early identification and precise prevention and control of the progression risk of AD.

Who May Be Eligible (Plain English)

Who May Qualify: - (1) Patients aged 40 years or older; - (2) Visiting Xuanwu Hospital, Capital Medical University; - (3) Meeting the core clinical diagnostic criteria for Alzheimer's disease (AD) - related mild cognitive impairment or probable AD according to the NIA-AA (2011); - (4) Amyloid positivity confirmed by amyloid PET or cerebrospinal fluid biomarker tests; - (5) Providing willing to sign a consent form. Who Should NOT Join This Trial: - (1) Individuals who are unable to complete the assessment due to severe psychological or physiological disorders. Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * (1) Patients aged 40 years or older; * (2) Visiting Xuanwu Hospital, Capital Medical University; * (3) Meeting the core clinical diagnostic criteria for Alzheimer's disease (AD) - related mild cognitive impairment or probable AD according to the NIA-AA (2011); * (4) Amyloid positivity confirmed by amyloid PET or cerebrospinal fluid biomarker tests; * (5) Providing informed consent. Exclusion Criteria: * (1) Individuals who are unable to complete the assessment due to severe psychological or physiological disorders.

Treatments Being Tested

OTHER

None-placebo

This study is an observational study, and no interventions will be implemented.

Locations (1)

Xuanwu Hospital of Capital Medical University
Beijing, Beijing Municipality, China